Loading provider…
Loading provider…
Internal Medicine Physician in Boston, MA
NPI: 1376834325Primary Practice Location
BRIGHAM AND WOMEN'S HOSPITAL
75 Francis St, Boston, MA
Primary Employer
Dana-Farber Cancer Institute
dana-farber.org
HQ Phone
Get MD Harshabad's Phone NumberMobile
Get MD Harshabad's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 36 | 165 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 32 | 32 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 20 | 48 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 14 | 16 |
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.
Authors: Alexander Jordan, Raja Narayan, James Cleary, Benjamin Weinberg, Rishi Surana, Andrew Aguirre, Rachna Shroff, Srivatsan Raghavan, George Sledge
Journal: Clin Cancer Res
Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.
Authors: Karen Ballen, Ilene Galinsky, Eyal Attar, Philip Amrein, Daniel Deangelo, Joseph Pidala
Publication Date: 2011-07
Lead Sponsor: Takeda
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: TAK-500
Lead Sponsor: Cancer Insight, LLC
Collaborators: Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Intervention / Treatment: DRUG: NG350A (Cohort C), DRUG: Nivolumab (Cohort A), DRUG: Ipilimumab (Cohort A, B and C), DRUG: Hydroxychloroquine (HCQ) (Cohort B), DRUG: Nab-paclitaxel (nP) (Cohort A, B and C), DRUG: Gemcitabine (gem) (Cohort A, B and C)